NanoViricides, Inc. (NYSE American: NNVC) announced continued progress advancing its broad-spectrum antiviral drug candidate NV-387 toward a Phase II clinical trial evaluating its oral gummies formulation as a treatment for the current Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo (DRC). The company said its proposed clinical trial has been approved by the DRC Pillar Committee, with preparations underway for ethics and regulatory submissions. NanoViricides noted that NV-387 is the only orally administered Ebola treatment candidate currently under consideration for clinical trials, offering potential advantages in resource-limited outbreak settings where infusion-based therapies can be difficult to deploy.
The company also highlighted the continued expansion of the outbreak, citing 1,561 confirmed cases and 506 deaths in the DRC as of July 6, while emphasizing that no approved treatment or vaccine currently exists for the Bundibugyo strain. NanoViricides said it believes NV-387’s broad-spectrum antiviral mechanism could provide activity against multiple ebolavirus strains and noted that the same oral gummies formulation has already received approval from DRC regulators for a Phase II trial in Mpox, with product already shipped to the country for that study. To view the full press release, visit https://ibn.fm/LaNwF.
NanoViricides, Inc. is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide class of drug candidates and technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
NV-387 is a broad-spectrum antiviral drug that the company plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections, and even Measles. The company is currently focused on advancing NV-387 into Phase II human clinical trials. The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC.
The approval of the proposed trial by the DRC Pillar Committee marks a significant step forward in addressing the ongoing outbreak. With no approved treatments for Bundibugyo ebolavirus, NV-387’s oral formulation could be a critical tool in containing the spread in remote areas. The company’s progress in both Ebola and Mpox trials underscores the potential of its broad-spectrum antiviral platform to address multiple viral threats.
